Boston, MA Clinical Trials Report — June 2026

For patients and healthy volunteers in Boston, MA, June 2026 presents a dynamic landscape of clinical research opportunities. With 2,648 clinical trials currently recruiting across 642 research facilities, Boston remains a hub for medical innovation. This month, a significant number of trials are nearing their enrollment deadlines, creating urgent opportunities for participation.

Act Now: Trials Closing Soon

Individuals interested in contributing to medical research should note that 210 clinical trials in Boston are scheduled to close within the next 90 days. This includes opportunities for healthy volunteers, with 38 of these rapidly closing studies still actively seeking participants without specific health conditions. Acting quickly can secure a spot in these time-sensitive research initiatives.

Patients managing specific health conditions also have limited time to join certain studies. Conditions with trials closing soon include:

• Prostate cancer (7 trials)
• Stroke (5 trials)
• Breast cancer (5 trials)
• Colorectal cancer (4 trials)
• Opioid use disorder (3 trials)
• Recurrent glioblastoma (3 trials)
• Major depressive disorder (3 trials)
• Glioblastoma (3 trials)
• AML (3 trials)
• Heart failure (3 trials)

New Research Opportunities Emerge in Boston

Boston saw the launch of 37 new clinical trials this month, a decrease from the 50 trials that opened in May 2026. Despite this slight dip, these new studies introduce significant opportunities across various medical fields.

Several notable new trials are now recruiting in Boston, including large-scale studies from prominent institutions and industry sponsors:

• Brigham and Women's Hospital is sponsoring NCT07619495, "Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk." This study aims to enroll 120,000 participants to build an empirical evidence base for real-world data by emulating randomized controlled trials.
• Also from Brigham and Women's Hospital, NCT07619508, "Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes," is a similar large-scale initiative targeting 100,000 participants to understand the utility of real-world data analyses.
• AstraZeneca is leading a Phase 3 study, NCT07662109, "A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus." This trial seeks 2,000 participants to evaluate a new combination therapy for type 2 diabetes mellitus.
• Dana-Farber Cancer Institute is sponsoring NCT07675967, "Clonal Hematopoiesis Chemotherapy and Radiation Effects Study," which plans to enroll 5,000 participants to understand how clonal hematopoiesis influences outcomes in people receiving chemotherapy and radiation for solid cancers.
• Stryker Endoscopy is sponsoring NCT07631468, "PROspect Registry :Post Market Clinical Follow-up Study," a retrospective, multi-center chart review involving 5,000 participants.
• Flo Health Inc. has launched NCT07630064, "Flo Digital Contraceptive Study," with 3,800 participants, to evaluate the effectiveness of the Flo Digital Contraceptive app in preventing unintended pregnancy.

New trials this month are exploring a range of conditions, with the most frequent being obesity (3 trials), overweight (3 trials), type 2 diabetes mellitus (2 trials), sickle cell disease (2 trials), sarcoma (2 trials), depression (2 trials), and ureteral stents (2 trials). Drug trials constitute the largest share of new studies, with 12 new drug trials, followed by 9 device trials and 8 other types of studies.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are consistent opportunities to contribute to research. Of the 37 new trials launched this month, 4 are actively seeking healthy volunteers. Across Boston, a total of 310 clinical trials are currently recruiting healthy participants, offering numerous avenues for those interested in supporting medical research without a specific diagnosis.

Boston's Leading Research Facilities

Boston is home to some of the nation's leading research institutions, which consistently conduct a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Massachusetts General Hospital (604 trials)
• Dana-Farber Cancer Institute (329 trials)
• Brigham and Women's Hospital (306 trials)
• Beth Israel Deaconess Medical Center (259 trials)
• Boston Children's Hospital (218 trials)
• Tufts Medical Center (108 trials)
• Boston Medical Center (99 trials)
• Massachusetts General Hospital Cancer Center (60 trials)

These institutions offer a broad spectrum of research, from oncology at Dana-Farber Cancer Institute and Massachusetts General Hospital Cancer Center, to diverse medical fields at Massachusetts General Hospital, Brigham and Women's Hospital, and Boston Children's Hospital.

Broadening Your Search: Nearby Massachusetts Options

While Boston offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Massachusetts. Cities with active trials include Waltham (7 trials), Methuen (3 trials), Cambridge (3 trials), New Bedford (3 trials), Worcester (2 trials), Chestnut Hill (1 trial), Fall River (1 trial), and Andover (1 trial).

Participation in clinical trials is open to a diverse range of individuals. Of the 37 new trials launched this month, 29 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 7 new trials include children, and 2 are female-only. Academic institutions continue to play a vital role in Boston's research ecosystem, with Massachusetts General Hospital (7 trials), Brigham and Women's Hospital (5 trials), and Dana-Farber Cancer Institute (3 trials) sponsoring the most new studies. Industry sponsors like AstraZeneca (2 trials) and Kallyope Inc. (2 trials) are also driving significant research efforts.

As Boston continues to drive medical innovation, the coming months will undoubtedly bring further opportunities for individuals to contribute to the future of healthcare.